Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Key Points Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it’s not for the faint of heart.

Hims & Hers Health has seen massive success, aided by the growing use of GLP-1 drugs. Click here to find out why I downgrade ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Per the chart above, roughly 35% of Hims & Hers float is sold short. Investors who short a stock are betting its price will fall. Short interest of 10% or more is considered unusually high. Not only ...

Hims & Hers leverages ZAVA's expertise to enter Europe's weight-loss market, boosting growth and profitability. Read what ...

Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its ...

Hims & Hers expanding in Europe with the purchase of London-based digital health platform ZAVA. The acquisition gives the ...

The E.U.'s universal healthcare policies make pharmaceuticals much more affordable relative to the U.S., meaning there could ...

Hims & Hers is the newest darling disrupting the telemedicine space. While shares have jumped 157% over the last year, Wall Street analysts don't seem overly bullish on the stock. Despite ...